Lecanemab IV + Placebo + Lecanemab SC
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Early Alzheimer's Disease
Conditions
Early Alzheimer's Disease
Trial Timeline
Mar 27, 2019 → Jun 30, 2029
NCT ID
NCT03887455About Lecanemab IV + Placebo + Lecanemab SC
Lecanemab IV + Placebo + Lecanemab SC is a phase 3 stage product being developed by Eisai for Early Alzheimer's Disease. The current trial status is active. This product is registered under clinical trial identifier NCT03887455. Target conditions include Early Alzheimer's Disease.
What happened to similar drugs?
2 of 20 similar drugs in Early Alzheimer's Disease were approved
Approved (2) Terminated (2) Active (17)
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03887455 | Phase 3 | Active |
Competing Products
20 competing products in Early Alzheimer's Disease